Navigation Links
GlySure CEO to Present CE Mark Trial Results at OneMedForum 2014
Date:1/7/2014

OXFORD, England, January 7, 2014 /PRNewswire/ --

GlySure reaches major milestone in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace

GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its European regulatory trial at the OneMedForum 2014 conference on January 13, 2014, in San Francisco.

OneMedForum 2014 will be the first time that the GlySure CEO Christopher Jones publicly presents the results of the multi-center CE Mark trial, which comprised 34 post surgery cardiac intensive care unit patients.

GlySure's announcement of the trial results marks the culmination of an exceptional year for the UK-based company. Since the start of 2013, GlySure has completed the development of the commercial version of its CBG monitor and sensor, secured ISO 13485 certification, completed a successful pilot trial on 24 cardiac ICU patients, recruited its European Director of Clinical Affairs, and delivered a successful European regulatory trial.

GlySure is currently compiling its CE Mark Technical File submission, which is the next step toward securing marketing approval of its CGBM technology in Europe. The company anticipates that it will make this submission in Q1.

"We are extremely pleased with the trial results demonstrating the ability to provide true continuous blood glucose monitoring on patients throughout their stay in cardiac intensive care," said GlySure CEO Christopher Jones. "We look forward to sharing these positive findings with the industry at OneMedForum in San Francisco next week."

OneMedForum 2014 will focus on areas of greatest investment opportunity in therapeutics, devices, diagnostics and health information and will also showcase the most promising microcap public companies and high growth private (pre-IPO) companies. More than 100 companies and 1,300 investors attend the annual event.

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  The company has demonstrated through ICU testing highly accurate sensors which can provide continuous glucose readings throughout the length of a patient's stay in the ICU.  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 30 employees. The company's products are not approved for use in the U.S. or Europe. http://www.glysure.com

Company Contact: Chris Jones, CEO, GlySure. Tel: +44(0)1235-462-870, cjones@glysure.com

Media Contact: Kara Della Vecchia, KDV Communications, Inc. Tel: +1-508-314-3127, kara@kdvcommunications.com


'/>"/>
SOURCE GlySure
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arcturus Therapeutics, Inc. to Present at the Biotech Showcase 2014
2. PAREXEL International To Present At JP Morgan Healthcare Conference
3. Orexigen Therapeutics to Present at the J.P. Morgan 2014 Healthcare Conference
4. Accuray to Present at JP Morgan 32nd Annual Healthcare Conference
5. Neurotrope, Inc., to Present at Biotech Showcase 2014 in San Francisco
6. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
7. Sigma-Aldrich Corporation To Present At 32nd Annual J.P. Morgan Healthcare Conference
8. Gateway Analytical to Present Latest Research at the Drug Delivery to the Lungs Conference in Edinburg, Scotland
9. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
10. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
11. Northwest Biotherapeutics to Present at the Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader ... “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, ... providing practical tips, tools, and strategies for clinical researchers. , “The landscape of ...
(Date:6/23/2016)... SILVER SPRING, Md. , June 23, 2016 ... evidence collected from the crime scene to track the criminal ... sick, and the U.S. Food and Drug Administration (FDA) uses ... Sound far-fetched? It,s not. ... whole genome sequencing to support investigations of foodborne illnesses. Put ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge ... envision new ways to harness living systems and biotechnology, ... Art (MoMA) in New York City ... 130 participating students, showcased projects at MoMA,s Celeste Bartos ... Paola Antonelli , MoMA,s senior curator of architecture and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)... May 3, 2016  Neurotechnology, a provider of ... MegaMatcher Automated Biometric Identification System (ABIS) , a ... projects. MegaMatcher ABIS can process multiple complex biometric ... combination of fingerprint, face or iris biometrics. It ... and MegaMatcher Accelerator , which have ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):